Close Menu

NEW YORK ─ BrainBox Solutions has begun enrolling patients for a clinical trial to evaluate the clinical utility of a diagnostic and prognostic test for mild traumatic brain injury and collect data for a submission to obtain marketing clearance from the US Food and Drug Administration.

The Richmond, Virginia-based company is developing an artificial intelligence-enabled, multimodality approach for the diagnosis and prognosis of mTBI, commonly referred to as a concussion.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.